1207745-58-1
Chemical Structure
MK-4409
- CAS No.: 1207745-58-1
- Formula:C22H17ClFN3O2S
- Molecular Weight:441.91
IUPAC Name: 2-(5-(5-((5-chloropyridin-2-yl)thio)-2-(4-fluorophenyl)oxazol-4-yl)pyridin-2-yl)propan-2-ol
InChIKey: DBZMCSVIITXLCC-UHFFFAOYSA-N
SMILES: CC(C)(O)C(C=C1)=NC=C1C2=C(SC3=NC=C(Cl)C=C3)OC(C4=CC=C(F)C=C4)=N2
Biological Activity: MK-4409 is an orally active and blood-brain barrier-penetrant fatty acid amide hydrolase (FAAH) inhibitor (human IC50 = 11 nM; rat IC50 = 11 nM) that reversibly and non-covalently inhibits this serine hydrolase, elevating endogenous fatty acid ethanolamides. MK-4409 alleviates inflammatory and neuropathic pain, with a long duration of action, and reduces edema. MK-4409 can be used for research on inflammatory and neuropathic pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MK-4409 | MK-4409 is an orally active and blood-brain barrier-penetrant fatty acid amide hydrolase (FAAH) inhibitor (human IC50 = 11 nM; rat IC50 = 11 nM) that reversibly and non-covalently inhibits this serine hydrolase, elevating endogenous fatty acid ethanolamides. MK-4409 alleviates inflammatory and neuropathic pain, with a long duration of action, and reduces edema. MK-4409 can be used for research on inflammatory and neuropathic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dariš B, et al. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosnian journal of basic medical sciences. 2019 Feb 12;19(1):14-23.
- [2]. Tuo W, et al. Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors. Journal of medicinal chemistry. 2017 Jan 12;60(1):4-46.
- [3]. Chobanian HR, et al. Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. ACS medicinal chemistry letters. 2014 Jun 12;5(6):717-21. [Content Brief]
